MA-VERACODE
28.8.2024 13:51:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the appointments of co-founder Chris Wysopal as Chief Security Evangelist and Jens Wessling as Chief Technology Officer (CTO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828594728/en/
Chris Wysopal (left) named Chief Security Evangelist and Jens Wessling (right) promoted to Chief Technology Officer (Photo: Business Wire)
Brian Roche, Chief Executive Officer at Veracode, said, "Developers and security teams turn to Veracode to help them build and maintain secure software as the broad adoption of AI increases security debt and exacerbates an unmanageable security backlog. As the leader in application risk management, we have the most effective solution on the market today to secure the software supply chain. Developers face a significant challenge in finding the right security platform among a sea of options, many of which are not equal. Chris Wysopal, a pioneer in the industry, will help us cut through the noise and amplify Veracode's voice and value. Through Chris’ and Jens’ leadership, we will continue to advance our solutions, deliver innovation, educate the market, and further support our customers and partners around the globe.”
As co-founder of Veracode, Wysopal helped shape the application security testing space and will continue to educate and train the wider tech community on cybersecurity best practices. In his new role as Chief Security Evangelist, he will leverage his 25 years’ experience to influence and advocate for Veracode’s products and services, impacting customers, prospects, influencers, analysts and policy makers. As a seasoned cybersecurity expert and trusted voice in the market, he will also spend time mentoring the next generation of cybersecurity professionals.
Wysopal said, "Chief Security Evangelist is a natural evolution of my role and fulfills my passion for ensuring security is at the heart of software development, deployment and maintenance. This is a perfect fit for me as I am passionate about helping security professionals at every level solve their most pressing cybersecurity challenges. I am equally proud to hand over the CTO reigns to Jens, who has a strong track record of driving technical excellence, so Veracode can deliver even more innovation and secure the software supply chain.”
Wessling has been promoted to Chief Technology Officer after serving as Vice President and Chief Architect since he joined the company in March 2024. Wessling came to Veracode with more than 25 years’ experience in cloud computing, data engineering and software development to architect Veracode’s increasingly interconnected solutions. In his new role as CTO, he will define and shape Veracode’s global technology strategy, in addition to leading the company’s research and product security teams.
Wessling said, "I am honored to expand my leadership role at Veracode—a company that has always been at the forefront of software security. Software supply chain security is one of the biggest challenges in cybersecurity, and I look forward to contributing even more as we help organizations build, buy and implement secure software.”
To learn more, watch the interview with Chris and Jens—broadcast live on Thursday August 29, 2024, at 11.30am Eastern Time and available afterward on demand.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828594728/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
